Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stella PharmaTSE:4888 +3.69%74 Days Inventory is 23,354.08 as of Mar. 2026, which is 165% above its 10-year median of 8,808.06. GuruFocus rates TSE:4888 with a GF Score™ of 74/100 and a GF Value™ of 円337.92 (Fairly Valued). The stock has 4 warning signs investors should review. Among 638 Biotechnology companies, Stella Pharma ranks worse than 98.75% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Stella Pharma's Average Total Inventories for the
six
months ended in Mar. 2026 was 円1,273.4 Mil. Stella Pharma's Cost of Goods Sold for the
six
months ended in Mar. 2026 was 円10.0 Mil.
Hence, Stella Pharma's Days Inventory for the
six
months ended in Mar. 2026 was 23,354.08.
The historical rank and industry rank for Stella Pharma's Days Inventory or its related term are showing as below:
TSE:4888'
s Days Inventory Range Over the Past 10 Years
Min: 3714.55 Med: 8808.06 Max: 14141.14
Current: 10390.44
During the past 8 years, Stella Pharma's highest Days Inventory was 14141.14. The lowest was 3714.55. And the median was 8808.06.
TSE:4888's Days Inventory is ranked worse than 98.75% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs TSE:4888: 10390.44
Stella Pharma's Days Inventory
increased
from Mar. 2025 (2,282.99) to Mar. 2026 (23,354.08).
It might indicate that Stella Pharma's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Stella Pharma's Inventory Turnover for the
six
months ended in Mar. 2026 was 0.01.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Stella Pharma's Inventory-to-Revenue for the
six
months ended in Mar. 2026 was 10.34.
Stella Pharma (TSE:4888) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Stella Pharma's Inventory Turnover for the
six
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Stella Pharma's Inventory to Revenue for the
six
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Stella Pharma Days Inventory Related Terms
Stella Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Stella Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4888 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Stella Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stella Pharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stella Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Stella Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stella Pharma (TSE:4888) has a Days Inventory of 23,354.08 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Stella Pharma and its competitors. This is 165% above median its historical median of 8,808.06. Over the past decade, Stella Pharma's Days Inventory has ranged from 3,714.55 to 14,141.14. According to the industry distribution chart, Stella Pharma ranks #630 out of 638 companies in the Biotechnology industry, placing it in the top 98.7%.
Is Stella Pharma's Days Inventory too high?
Stella Pharma's current Days Inventory of 23,354.08 is 165% above median its 10-year median of 8,808.06. Over the past 10 years, this metric has ranged from a low of 3,714.55 to a high of 14,141.14. The Biotechnology industry median Days Inventory is 183.20. Stella Pharma's value of 23,354.08 is 12648.2% above this industry median. Based on the distribution chart, Stella Pharma ranks #630 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stella Pharma has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stella Pharma ranks #630 out of 638 companies for Days Inventory. This places Stella Pharma in the lower half of its industry. The industry median Days Inventory is 183.20. Stella Pharma's value of 23,354.08 is 12648.2% above this benchmark. Historically, Stella Pharma's own Days Inventory has ranged from 3,714.55 to 14,141.14 over the past decade. While the company's 10-year median is 8,808.06 vs. the industry median of 183.20, Stella Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stella Pharma's current Days Inventory of 23,354.08 is 12648.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Stella Pharma and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stella Pharma's current Days Inventory is 23,354.08, which is 165% above median its own 10-year median of 8,808.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Fairly Valued. The stock's GF Value™ is 円337.92, compared to a current price of 円337.00 — trading 0.3% below its estimated fair value. The current Days Inventory is 23,354.08, which is 165% above median its 10-year median of 8,808.06 and 12648.2% above the Biotechnology industry median of 183.20. Stella Pharma's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current Days Inventory is 23,354.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stella Pharma (TSE:4888) Overvalued in 2026?
Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued.
The current stock price of 円337.00 is trading 0.3% below its estimated GF Value™ of 円337.92.
GuruFocus considers Stella Pharma to be Fairly Valued.
Key valuation signals for TSE:4888:
Days Inventory: 23,354.08 (165% above median its 10-year median of 8,808.06)
GF Value™: 円337.92 vs. price of 円337.00 (0.3% below fair value)
Industry Position: 12648.2% above the Biotechnology median (#630 of 638)
No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
74GF Score
Get the complete analysis for TSE:4888
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4888 has been successfully added to your 
